Sign in
CRSP Stock Price, Chart, Stats & News
CRISPR Therapeutics AG
Save
5.02B
Market cap
–
Current P/E
23.36x
Forward P/E
CRSP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -8560.01% |
Operating margin | -25384.68% |
Pretax margin | -22076.59% |
Net margin | -22215.39% |
Effective tax rate | -0.63% |
ROA | -25.67% |
ROE | -31.53% |
D/E | 0.21x |
Interest coverage ratio | – |
CRSP valuation
P/E | – |
P/S | 1677.36x |
P/B | 2.14x |
P/CF | -11.92x |
P/FCF | -12.69x |
P/OCF | -11.92x |
PEG | 0.43x |
EV multiple | -7.03x |
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Similar securities
Based on sector and market capitalization
Report issue